Emilija Cvetkovska
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Emilija Cvetkovska has a total of 20 co-authors. Here are the top co-authors by number of shared publications:
- Marija Babunovska
Department of Neurology, Ss. Cyril and Methodius University Faculty of Medicine, Skopje, North Macedonia
5 shared publications Bojan Boskovski
University Clinic for Neurology Faculty of Medicine, Ss. Cyril and Methodius University, Skopje, North Macedonia
2 shared publications- Dijana Plaseska-Karanfilska
Research Centre for Genetic Engineering and Biotechnology "Georgi D. Efremov", Macedonian Academy of Science and Arts, Skopje, North Macedonia
2 shared publications Gordana Kiteva Trencevska
University Clinic for Neurology, Faculty of Medicine Ss. Cyril and Methodius University Skopje North Macedonia
2 shared publicationsIgor Kuzmanovski
University Clinic for Neurology Faculty of Medicine, Ss. Cyril and Methodius University, Skopje, North Macedonia
2 shared publications- Igor Kuzmanovski
Institute of Chemistry, Faculty of Natural Sciences and Mathematics, Ss. Cyril and Methodius University in Skopje, North Macedonia
2 shared publications
Latest Publications
- Open Access
- 9 July 2026
- Published by Galenos Yayinevi in Balkan Medical Journal
- Vol. 43 (7) , 407-410
Genotype-Phenotype Correlation in Tuberous Sclerosis Complex: Insights from North Macedonia
- 9 July 2026
- Published by Galenos Yayinevi in Balkan Medical Journal
- Vol. 43 (7) , 407-410
Open AccessGenotype-Phenotype Correlation in Tuberous Sclerosis Complex: Insights from North Macedonia
- 29 December 2025
- Published by Elsevier in Clinical Neurology and Neurosurgery
- Vol. 262, 109302
Incidence, risk factors and management practices in post-viral encephalitis epilepsy: A long-term, nationwide population-based study and review of literature
- 29 December 2025
- Published by Elsevier in Clinical Neurology and Neurosurgery
- Vol. 262, 109302
Incidence, risk factors and management practices in post-viral encephalitis epilepsy: A long-term, nationwide population-based study and review of literature
- 16 March 2024
- Published by Elsevier in Pediatric Neurology
- Vol. 155, 51-54
Novel Variant ANKRD11 Gene Mutation Associated With Drug-Resistant Epilepsy in KBG Syndrome Phenotype
- 16 March 2024
- Published by Elsevier in Pediatric Neurology
- Vol. 155, 51-54
Novel Variant ANKRD11 Gene Mutation Associated With Drug-Resistant Epilepsy in KBG Syndrome Phenotype
- Open Access
- 25 June 2023
- Published by Wiley in Epilepsia Open
- Vol. 8 (3) , 1028-1037
Fractures in people with epilepsy: A nationwide population‐based cohort study
Objective: The objective of this study was to determine the age, gender, and site‐specific prevalence of fractures in people with epilepsy (PWE) and matched general population comparators in a nationwide study in North Macedonia between 2015 and 2018.Methods: PWE and matched controls were selected through a systematic search of the electronic National Health System (eNHS). We determined the period prevalence (PP) of all site‐specific fractures. We also calculated gender and age‐specific incidence rate ratios (IRR) for various fractures. Odds ratios (ORs) and risk ratios (RR) were estimated for the number and type of ASM as well as comorbid conditions.Results: Out of 13 818 prevalent epilepsy cases, 6383 (46.2%) were females, and 7435 (53.8%) were males. 109 PWE out of 1000 had at least one fracture during the study period and ~8 people out of 1000 in the general population. The most frequent sites in terms of PP both in PWE and controls, were fractures of the lower arm, hip and femur, and lower leg. Significant differences in PP for all fracture locations were observed between PWE and controls (P < 0.001). The noticeable differences of ∼100 times higher PP were observed for fractures of the skull and jaw in PWE. IRR of any fracture in PWE was 272.84/10 000 person‐years; higher in the older age groups and among people who received >2 ASM. Fracture risk was increased with the use of >2 ASM (OR: 1.56; 95% CI: 1.32‐1.84 and RR: RR: 1.32). The presence of comorbidities also increased fractures risk (OR: 1.24; 95% CI: 1.10‐1.38).Significance: This population‐based study depicts a higher fracture prevalence in PWE compared to the general population. A higher number of ASM and the presence of comorbidities increase the risk of fractures and targeted prevention might be needed in those subgroups of PWE.
- 25 June 2023
- Published by Wiley in Epilepsia Open
- Vol. 8 (3) , 1028-1037
Open AccessFractures in people with epilepsy: A nationwide population‐based cohort study
Objective: The objective of this study was to determine the age, gender, and site‐specific prevalence of fractures in people with epilepsy (PWE) and matched general population comparators in a nationwide study in North Macedonia between 2015 and 2018.Methods: PWE and matched controls were selected through a systematic search of the electronic National Health System (eNHS). We determined the period prevalence (PP) of all site‐specific fractures. We also calculated gender and age‐specific incidence rate ratios (IRR) for various fractures. Odds ratios (ORs) and risk ratios (RR) were estimated for the number and type of ASM as well as comorbid conditions.Results: Out of 13 818 prevalent epilepsy cases, 6383 (46.2%) were females, and 7435 (53.8%) were males. 109 PWE out of 1000 had at least one fracture during the study period and ~8 people out of 1000 in the general population. The most frequent sites in terms of PP both in PWE and controls, were fractures of the lower arm, hip and femur, and lower leg. Significant differences in PP for all fracture locations were observed between PWE and controls (P < 0.001). The noticeable differences of ∼100 times higher PP were observed for fractures of the skull and jaw in PWE. IRR of any fracture in PWE was 272.84/10 000 person‐years; higher in the older age groups and among people who received >2 ASM. Fracture risk was increased with the use of >2 ASM (OR: 1.56; 95% CI: 1.32‐1.84 and RR: RR: 1.32). The presence of comorbidities also increased fractures risk (OR: 1.24; 95% CI: 1.10‐1.38).Significance: This population‐based study depicts a higher fracture prevalence in PWE compared to the general population. A higher number of ASM and the presence of comorbidities increase the risk of fractures and targeted prevention might be needed in those subgroups of PWE.
- 1 November 2018
- Published by Wolters Kluwer Health in Clinical Neuropharmacology
- Vol. 41 (6) , 218-221
Levetiracetam-Induced Seizure Aggravation in Patients With Focal Cortical Dysplasia
Objectives: The choice of antiepileptic drug is typically based on seizure type, and there is no evidence for superior effectiveness or potential deterioration of particular antiepileptic drug in specific etiologic subgroups. The aim of the study was to identify etiological factor(s) associated with increased risk of seizure aggravation with levetiracetam (LEV). Methods: A retrospective analysis of 139 patients treated with LEV was performed. Seizure aggravation was defined as a 100% or greater increase in seizures frequency, which occurred within 1 month of drug introduction. Results: Five patients who fulfilled the selection criteria were identified. Seizure aggravation occurred with low doses (500–1000 mg) of LEV. In addition to increased frequency and duration, 2 patients developed new seizure types. Withdrawal of LEV resulted in seizure return to background frequency in all patients. Four of 5 patients have distinctive magnetic resonance imaging finding of focal cortical dysplasia. No patients with paradoxical effect of LEV were detected in the idiopathic epilepsy group or other types of symptomatic epilepsies. Conclusions: Our results suggest that LEV may possibly induce seizure exacerbation in a subset of patients with focal cortical dysplasia–related epilepsy, although large studies are needed to establish the relation. Underlying causes of epilepsy could impact the treatment choice because electroclinical semiology might be the “final common pathway” of different epileptogenic mechanisms in diverse etiologies.
- 1 November 2018
- Published by Wolters Kluwer Health in Clinical Neuropharmacology
- Vol. 41 (6) , 218-221
Levetiracetam-Induced Seizure Aggravation in Patients With Focal Cortical Dysplasia
Objectives: The choice of antiepileptic drug is typically based on seizure type, and there is no evidence for superior effectiveness or potential deterioration of particular antiepileptic drug in specific etiologic subgroups. The aim of the study was to identify etiological factor(s) associated with increased risk of seizure aggravation with levetiracetam (LEV). Methods: A retrospective analysis of 139 patients treated with LEV was performed. Seizure aggravation was defined as a 100% or greater increase in seizures frequency, which occurred within 1 month of drug introduction. Results: Five patients who fulfilled the selection criteria were identified. Seizure aggravation occurred with low doses (500–1000 mg) of LEV. In addition to increased frequency and duration, 2 patients developed new seizure types. Withdrawal of LEV resulted in seizure return to background frequency in all patients. Four of 5 patients have distinctive magnetic resonance imaging finding of focal cortical dysplasia. No patients with paradoxical effect of LEV were detected in the idiopathic epilepsy group or other types of symptomatic epilepsies. Conclusions: Our results suggest that LEV may possibly induce seizure exacerbation in a subset of patients with focal cortical dysplasia–related epilepsy, although large studies are needed to establish the relation. Underlying causes of epilepsy could impact the treatment choice because electroclinical semiology might be the “final common pathway” of different epileptogenic mechanisms in diverse etiologies.